Lantern Pharma Inc.

NasdaqCM LTRN

Lantern Pharma Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -17.23 M

Lantern Pharma Inc. Operating Cash Flow is USD -17.23 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -26.39% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Lantern Pharma Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -13.63 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: LTRN

Lantern Pharma Inc.

CEO	Mr. Panna Sharma PH.D.
IPO Date	June 11, 2020
Location	United States
Headquarters	1920 McKinney Avenue
Employees	21
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Key trends

Past 5 years